P-21 Peptide vs SNAP-8 (Acetyl Octapeptide-3)
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
P-21 Peptide
Short neuropeptide based on the activity-dependent neurotrophic factor (ADNF) family with potent neuroprotective effects demonstrated in Alzheimer's disease models. Distinct from the cell cycle inhibitor protein p21/CDKN1A. Reduces amyloid-beta burden, improves cognitive outcomes in rodent models, and modulates neuroinflammation through STAT3 and JAK2 signaling pathways.
Full profileSNAP-8 (Acetyl Octapeptide-3)
8-amino acid cosmetic peptide active (Acetyl Octapeptide-3) that competes with SNARE complex proteins to reduce neuromuscular signal transmission in facial expression muscles. An extended, more potent version of Argireline (Acetyl Hexapeptide-3). Clinical studies show 26–63% reduction in expression wrinkle depth with twice-daily application, positioning it as a topical botulinum toxin alternative.
Full profile| P-21 Peptide | SNAP-8 (Acetyl Octapeptide-3) | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | P21, Colivelin fragment, P21 neuropeptide, ADNF-related neuropeptide | Leuphasyl, Acetyl Octapeptide-3, SNAP-8 peptide, Argireline extension, Acetyl Glutamyl Heptapeptide-3 |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 5mcg–20mcg mcg, daily or every other day (intranasal or SC) | 1%–10% %, twice daily topical application |
| Administration | Intranasal, Subcutaneous injection | Topical (serum/cream) |
| Key side effects | Limited human safety data, In animal studies: well-tolerated at therapeutic doses, Theoretical STAT3 pathway concerns with chronic use (pro-survival signaling), Nasal irritation (intranasal route) | Very well-tolerated, Rare mild skin irritation or redness, No systemic absorption at cosmetic concentrations, No paralysis risk (partial SNARE competition only) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: P-21 Peptide is preclinical only, while SNAP-8 (Acetyl Octapeptide-3) is research-stage.
- Administration: P-21 Peptide — Intranasal, Subcutaneous injection; SNAP-8 (Acetyl Octapeptide-3) — Topical (serum/cream).
- Dosing units differ: P-21 Peptide is dosed in mcg, SNAP-8 (Acetyl Octapeptide-3) in % — they operate at different scales.
- Frequency: P-21 Peptide is typically daily or every other day (intranasal or SC); SNAP-8 (Acetyl Octapeptide-3) is twice daily topical application.
How each works
P-21 Peptide
P-21 activates STAT3/JAK2 signaling through CNTF-related pathways, reducing amyloid-beta toxicity by activating amyloid-clearing enzymes (insulin-degrading enzyme, neprilysin) and inhibiting tau phosphorylation. Derived from the colivelin family of neuroprotective peptides, P-21 demonstrates cognitive improvement in Alzheimer's mouse models at doses far below cytotoxic levels. Human data remains limited.
SNAP-8 (Acetyl Octapeptide-3)
SNAP-8 mimics the N-terminal domain of SNAP-25, competing for SNARE complex assembly required for acetylcholine vesicle fusion at the neuromuscular junction. This partial inhibition reduces muscle contraction intensity without complete paralysis. Clinical studies demonstrate statistically significant reductions in crow's feet and forehead line depth after 28 days of use at 5–10% concentration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.